125 related articles for article (PubMed ID: 38461693)
1. Progress in long non-coding RNAs as prognostic factors of papillary thyroid carcinoma.
Zhu HN; Song DL; Zhang SN; Zheng ZJ; Chen XY; Jin X
Pathol Res Pract; 2024 Apr; 256():155230. PubMed ID: 38461693
[TBL] [Abstract][Full Text] [Related]
2. BRAF
Shi C; Cao J; Shi T; Liang M; Ding C; Lv Y; Zhang W; Li C; Gao W; Wu G; Man J
World J Surg Oncol; 2020 Jun; 18(1):145. PubMed ID: 32593310
[TBL] [Abstract][Full Text] [Related]
3. Identification of Specific Long Non-Coding RNA Expression: Profile and Analysis of Association with Clinicopathologic Characteristics and BRAF Mutation in Papillary Thyroid Cancer.
Wang Q; Yang H; Wu L; Yao J; Meng X; Jiang H; Xiao C; Wu F
Thyroid; 2016 Dec; 26(12):1719-1732. PubMed ID: 27758138
[TBL] [Abstract][Full Text] [Related]
4. Genome-Wide Expression Screening Discloses Long Noncoding RNAs Involved in Thyroid Carcinogenesis.
Liyanarachchi S; Li W; Yan P; Bundschuh R; Brock P; Senter L; Ringel MD; de la Chapelle A; He H
J Clin Endocrinol Metab; 2016 Nov; 101(11):4005-4013. PubMed ID: 27459529
[TBL] [Abstract][Full Text] [Related]
5. BRAF-activated LncRNA functions as a tumor suppressor in papillary thyroid cancer.
Liao T; Qu N; Shi RL; Guo K; Ma B; Cao YM; Xiang J; Lu ZW; Zhu YX; Li DS; Ji QH
Oncotarget; 2017 Jan; 8(1):238-247. PubMed ID: 27462868
[TBL] [Abstract][Full Text] [Related]
6. Noncoding RNAs in Papillary Thyroid Cancer: Interaction with Cancer-Associated Fibroblasts (CAFs) in the Tumor Microenvironment (TME) and Regulators of Differentiation and Lymph Node Metastasis.
Dadafarin S; Carnazza M; Islam HK; Moscatello A; Tiwari RK; Geliebter J
Adv Exp Med Biol; 2021; 1350():145-155. PubMed ID: 34888848
[TBL] [Abstract][Full Text] [Related]
7. Integrated analysis identifying new lncRNA markers revealed in ceRNA network for tumor recurrence in papillary thyroid carcinoma and build of nomogram.
Chen F; Li Z; Deng C; Yan H
J Cell Biochem; 2019 Dec; 120(12):19673-19683. PubMed ID: 31271223
[TBL] [Abstract][Full Text] [Related]
8. The role of BRAF V600E mutation as a potential marker for prognostic stratification of papillary thyroid carcinoma: a long-term follow-up study.
Daliri M; Abbaszadegan MR; Bahar MM; Arabi A; Yadollahi M; Ghafari A; Taghehchian N; Zakavi SR
Endocr Res; 2014; 39(4):189-93. PubMed ID: 24679337
[TBL] [Abstract][Full Text] [Related]
9. BRAF mutation in papillary thyroid cancer and its value in tailoring initial treatment: a systematic review and meta-analysis.
Tufano RP; Teixeira GV; Bishop J; Carson KA; Xing M
Medicine (Baltimore); 2012 Sep; 91(5):274-286. PubMed ID: 22932786
[TBL] [Abstract][Full Text] [Related]
10. Risk and Prognostic Factors for BRAF
Wei X; Wang X; Xiong J; Li C; Liao Y; Zhu Y; Mao J
Biomed Res Int; 2022; 2022():9959649. PubMed ID: 35647194
[TBL] [Abstract][Full Text] [Related]
11. Long intergenic non-coding RNA 271 is predictive of a poorer prognosis of papillary thyroid cancer.
Ma B; Liao T; Wen D; Dong C; Zhou L; Yang S; Wang Y; Ji Q
Sci Rep; 2016 Nov; 6():36973. PubMed ID: 27833134
[TBL] [Abstract][Full Text] [Related]
12. Risk factors for central lymph node metastasis in patients with papillary thyroid carcinoma: a retrospective study.
Du J; Yang Q; Sun Y; Shi P; Xu H; Chen X; Dong T; Shi W; Wang Y; Song Z; Shang X; Tian X
Front Endocrinol (Lausanne); 2023; 14():1288527. PubMed ID: 38047112
[TBL] [Abstract][Full Text] [Related]
13. MUC1 expression in papillary thyroid carcinoma is associated with BRAF mutation and lymph node metastasis; the latter is the most important risk factor of relapse.
Renaud F; Gnemmi V; Devos P; Aubert S; Crépin M; Coppin L; Ramdane N; Bouchindhomme B; d'Herbomez M; Van Seuningen I; Do Cao C; Pattou F; Carnaille B; Pigny P; Wémeau JL; Leteurtre E
Thyroid; 2014 Sep; 24(9):1375-84. PubMed ID: 25012490
[TBL] [Abstract][Full Text] [Related]
14. [Clinical pathological characteristics of resectable papillary thyroid microcarcinoma].
Shi CL; Guo Y; Lyu YC; Nanding ZABYS; Gao WC; Shi TF; Qin HD; Liu SY
Zhonghua Zhong Liu Za Zhi; 2017 May; 39(5):361-366. PubMed ID: 28535653
[No Abstract] [Full Text] [Related]
15. Elevated BANCR expression levels have different effects on papillary thyroid carcinoma progression depending on the presence of the BRAFV600E mutation.
Stojanović S; Šelemetjev S; Đorić I; Rončević J; Janković Miljuš J; Živaljević V; Išić Denčić T
Eur J Surg Oncol; 2020 Oct; 46(10 Pt A):1835-1842. PubMed ID: 32651027
[TBL] [Abstract][Full Text] [Related]
16. Long Non-Coding RNAs Profiling Using Microarray in Papillary Thyroid Carcinoma.
Islam F; Zhou Y; Lam AK
Methods Mol Biol; 2022; 2534():135-148. PubMed ID: 35670973
[TBL] [Abstract][Full Text] [Related]
17. Role of differentially expressed genes and long non-coding RNAs in papillary thyroid carcinoma diagnosis, progression, and prognosis.
Cai WY; Chen X; Chen LP; Li Q; Du XJ; Zhou YY
J Cell Biochem; 2018 Nov; 119(10):8249-8259. PubMed ID: 29968931
[TBL] [Abstract][Full Text] [Related]
18. BRAF mutation in papillary thyroid cancer: pathogenic role, molecular bases, and clinical implications.
Xing M
Endocr Rev; 2007 Dec; 28(7):742-62. PubMed ID: 17940185
[TBL] [Abstract][Full Text] [Related]
19. Construction of a Tumor Immune Microenvironment-Related Prognostic Model in BRAF-Mutated Papillary Thyroid Cancer.
Xia Y; Jiang X; Huang Y; Liu Q; Huang Y; Zhang B; Mei Z; Xu D; Shi Y; Tu W
Front Endocrinol (Lausanne); 2022; 13():895428. PubMed ID: 35757399
[TBL] [Abstract][Full Text] [Related]
20. Identification of a Recurrent LMO7-BRAF Fusion in Papillary Thyroid Carcinoma.
He H; Li W; Yan P; Bundschuh R; Killian JA; Labanowska J; Brock P; Shen R; Heerema NA; de la Chapelle A
Thyroid; 2018 Jun; 28(6):748-754. PubMed ID: 29768105
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
